Engineered immune cells take aim at Hard-to-Treat lymphoma
NCT ID NCT07453446
First seen Mar 08, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This study was designed to test a new treatment called CD30-targeted CAR-T cells for people with lymphoma that has returned or not responded to standard therapy. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The study aimed to check safety and early signs of effectiveness, but it was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hebei Yanda Lu Daopei Hospital
Sanhe, China
Conditions
Explore the condition pages connected to this study.